Smith & Nephew buys cartilage repair product from Piramal

Smith & Nephew ($SNN) sees the arthroscopically delivered cartilage repair solution it's just bought from Montreal, Canada-based Piramal for an undisclosed sum as a first-line treatment. Known as BST-CarGel, it's approved in most of Europe, Australia and Canada.

BST-CarGel is a biopolymer-based solution. It's first mixed with a patient's blood and then implanted into the joint after a microfracture procedure. It can be used to treat damaged cartilage in synovial joints such as the knee, hip, ankle and shoulder.

Microfracture is a surgical technique for cartilage repair that creates tiny fractures in the underlying bone and creates what is called a "super-clot." BST-CarGel is designed to adhere to the cartilage surface and stabilize the blood clot while new cartilage is regenerated.

"BST-CarGel augments our existing joint repair portfolio with a new option that is differentiated with strong clinical evidence and targets an area of significant patient need and surgeon demand," said VP of Sports Medicine at S&N Scott Schaffner in a statement. "We are committed to seeking and investing in next-generation technologies to widen access across our global customer base."

In an 80-patient trial among those with grade III and IV femoral cartilage lesions demonstrated that microfracture, BST-CarGel showed better quantity and quality of repair tissue at one and 5 years after microfracture alone. It also had fewer structural failures after 5 years.

Smith & Nephew's Sports Medicine business is built around its 2014 acquisition of Arthrocare for about $1.7 billion. In the first 9 months of 2015, the company reported $437 million specifically in joint repair revenue. That's an increase of 5% over the same period a year earlier. That makes it a bit of laggard in the overarching Sports Medicine revenues, which were about $1.4 billion and grew at a 9% pace in the first 9 months of 2015.

- here is the announcement

Suggested Articles

Millions of tests are urgently needed as the virus keeps communities across the country in lockdown and hospitals are overwhelmed with patients.

The FDA granted its first emergency authorization for a rapid antibody blood test for COVID-19 developed by Cellex.

The ultimate goal is to move as many patients as possible out of the clinic that don’t need immediate, critical care.